Medication info
Lureka OD Tablet 75 mg (Pregabalin)

Lureka OD Tablet 75 mg (Pregabalin)

Prescription medicationOrally disintegrating Tablet
Ingredient · strength
Pregabalin›75mg / 1 tablet
Manufacturer / importer
Huons Lifescience Co., Ltd.
Appearance
Light orange rhomboid orally disintegrating tablet
Packaging
30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]
Approval status
Active

MFDS item code 202600533 · Approved 2026.02.24

Summary

Main use
Treatment of neuropathic pain; adjunctive treatment of partial seizures and treatment of fibromyalgia
Who uses it
Adults · Children
Adult dosage
Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. Place the tablet on the tongue and, once it disintegrates, swallow without water. 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section 4. Discontinuation of treatment.) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day); depending on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, administer a supplemental dose promptly after each 4-hour hemodialysis session. ≥60 mL/min: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60 mL/min: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30 mL/min: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15 mL/min: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Huons Lifescience Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain; adjunctive treatment of partial seizures and treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also prescribed as an adjunct for partial seizures in epilepsy patients and is effective for relieving fibromyalgia symptoms. It is used for the management of various neurological disorders and pain.

Dosage and Administration

Adult dosage

Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. Place the tablet on the tongue and, once it disintegrates, swallow without water. 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section 4. Discontinuation of treatment.) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day); depending on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, administer a supplemental dose promptly after each 4-hour hemodialysis session. ≥60 mL/min: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60 mL/min: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30 mL/min: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15 mL/min: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication, as an anticonvulsant, may increase the risk of suicidal thoughts or behaviors, so it is important to consult a physician immediately if there are any changes in mood or behavior during treatment. Patients with hypersensitivity to this medication should not use it. Diabetic patients should be cautious as weight gain may require adjustment in blood sugar control medications. If serious allergic reactions such as angioedema occur, discontinue the medication immediately and inform healthcare professionals. Elderly patients should be particularly careful at the start of treatment due to the risk of falls from dizziness or drowsiness. Vision changes or blurred vision may occur, and it is advisable to consult a physician if these symptoms arise. Discontinuing this medication suddenly may result in withdrawal symptoms such as insomnia, headache, and anxiety; therefore, it should be gradually reduced under a physician's guidance. Due to the risk of drug abuse, patients with a history of substance abuse should exercise increased caution. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should be cautious as edema or symptoms of heart failure may occur with this medication. This medication has central nervous system depressant effects; caution is advised when taking it with other sedatives or opioid analgesics due to an increased risk of respiratory depression. During early pregnancy, it may affect the fetus, so women who are pregnant or planning to become pregnant should consult a physician before use and should use effective contraception. Breastfeeding women should avoid breastfeeding while taking this medication as it may pass into breast milk and affect the baby. Activities requiring attention, such as driving or operating machinery, should be avoided until the dizziness or drowsiness from this medication subsides. In case of overdose, symptoms such as confusion, drowsiness, and seizures may occur, and emergency treatment should be sought immediately. This medication should be kept out of reach of children and should not be transferred to other containers for safety.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • angioedema
  • facial swelling
  • perioral edema
  • upper respiratory tract edema
  • dizziness
  • drowsiness
  • loss of consciousness
Show 200 more
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • insomnia
  • depersonalization
  • sexual hypersensitivity
  • restlessness
  • anxiety
  • mood disturbance
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • ataxia
  • movement coordination impairment
  • balance disorders
  • amnesia
  • attention disorder
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • drowsiness
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonus
  • reflex reduction
  • movement disorders
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • tremor during activity
  • syncope
  • confusion
  • decreased mobility
  • olfactory disturbance
  • taste loss
  • writing difficulty
  • blurred vision
  • double vision
  • indirect vision loss
  • visual impairment
  • visual field loss
  • photophobia
  • dry eyes
  • eye swelling
  • decreased vision
  • ocular pain
  • eye fatigue
  • increased tear secretion
  • ocular irritation
  • pupil dilation
  • during vibration
  • depth perception changes in vision
  • strabismus
  • brightness of vision
  • lightheadedness
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • hypersalivation
  • gastroesophageal reflux
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • reduced urine output
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • swelling
  • gait abnormalities
  • falls
  • feeling drunk
  • sensory abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased blood potassium
  • increased blood creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • malaise
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • agitation
  • restlessness
  • worsening of convulsions
  • gastrointestinal disorders
  • tinnitus
  • sleep disorders
  • skin diseases
  • increased BUN
  • blood in stool

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from exposure to air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Light orange rhomboid orally disintegrating tablet

Package unit

30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.